Economic assessment of thrombocytopenia: CATCH Registry.
Thrombocytopenia is associated with increased patient risk. However, the costs of this complication are not well defined. This study assessed the impact of thrombocytopenia on in-hospital costs using results from CATCH, an observational study that examined 1988 consecutive patients receiving prolonged heparin therapy (> or =96 h). Thrombocytopenia was defined as: (group 1) an absolute reduction in platelet count to <150 x 10(9)/L; (group 2) a relative reduction in platelet count of >50% from admission levels; or (group 3) both criteria. We found that the development of thrombocytopenia was associated with significantly higher total in-hospital costs for all groups: (group 1) (difference, $8,222; 95% CI, $5,020-$11,425; P<.001); (group 2) (difference, $15,429; 95% CI, $7,472-$23,385; P<.001); and (group 3) (difference, $27,077; 95% CI, $22,901-$31,252; P<.001). However, in our adjusted model, longer lengths-of-stay and greater use of blood transfusions accounted for most incremental in-hospital cost differences.
Eisenstein
Eric L
EL
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA. eric.eisenstein@duke.edu
Honeycutt
Emily F
EF
Anstrom
Kevin J
KJ
Becker
Richard C
RC
Granger
Christopher B
CB
Rao
Sunil V
SV
Jolicoeur
Marc E
ME
Ohman
E Magnus
EM
D000368:Aged; D001803:Blood Transfusion / Q000191:economics / Q000706:statistics & numerical data; D003365:Costs and Cost Analysis; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects; D006493:Heparin / Q000009:adverse effects; D017721:Hospital Costs / Q000706:statistics & numerical data*; D006801:Humans; D007902:Length of Stay / Q000191:economics / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D012042:Registries; D013921:Thrombocytopenia / Q000139:chemically induced / Q000191:economics* / Q000628:therapy; D014481:United States
D005343:Fibrinolytic Agents; D006493:Heparin